王慧

1999年在天津醫科大學/美國伯明翰阿拉巴馬大學(UAB)獲得醫學、理學博士學位(中美聯合培養)；1999年至2001年在美國UAB大學從事博士后研究；之後在美國UAB大學臨床藥理部、藥理與毒理系任講師(2001-2002)、助理教授及癌症藥理學中心實驗室副主任(2002-2005)；2005年10月至今任中國科學院上海生命科學研究院營養科學研究所研究員、博士生導師、研究組長，食品安全研究中心主任(2007-)，國家食品安全風險評估中心中科院上海生科院分中心常務副主任(2013-)，中國科學院食品安全重點實驗室(籌)主任(2014-)，所長專項助理（2014-）。長期從事腫瘤分子靶點、營養藥學、食品安全的基礎和應用研究，任國內外多家雜誌編委。現任國務院食品安全委員會專家委員會委員，第一屆食品安全國家標準審評委員會委員、微生物分委員會主任委員，中國毒理學會第六屆理事會理事、毒理學替代法與轉化毒理學專業委員會常委，中國抗癌協會腫瘤病因學專業委員會委員，國家科學技術獎評審專家，國家食品藥品監督管理總局保健食品和新葯審評專家，衛生計生委食品安全審評專家，衛生計生委新食品原料評審專家，上海市食品安全委員會專家組成員，上海市食品安全地方標準審評委員會專家委員會委員。

2006年入選上海市“浦江人才計劃”，2007年入選中國科學院“百人計劃”， 2011年獲得國家傑出青年科學基金資助，2011年被評為上海市科技系統三八紅旗手， 2012年入選上海市優秀學術帶頭人，2013年獲得中國青年女科學家獎，2014年獲得明治生命科學獎優秀獎，2015年獲得上海市三八紅旗手，2015年獲得第十四屆“上海市科技精英”提名獎，2016年獲得首屆女科技工作者社會服務獎。

(1) 腫瘤分子靶點和營養藥學的應用基礎研究：發現腫瘤人群易感標誌物和診斷治療新靶點，研究靶點功能及其分子調控和信號轉導，探索以膳食營養素、天然植物活性成份、化學小分子探針等靶向干預和治療腫瘤的新機制和新方法。

(2) 營養和食品安全的基礎和應用研究：營養成分安全性評價及毒理學研究，營養素和營養素物質的安全劑量，過量時的毒理作用以及機制；食物中有毒有害物質代謝途徑和致病機理，食品安全風險評估、預防控制和檢測新技術研究。

Ba Q, Huang C, Fu Y, Li J, Li J, Chu R, Jia X,Wang H*. Cumulative metabolic effects of low-dose benzo(a)pyrene exposure on human cells.Toxicology Research. 2016;5:107-115. (*Corresponding author)

Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X,Wang H*. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.Gut. 2015 Oct 9. (*Corresponding author)

Zhang X, Ba Q, Gu Z, Guo D, Zhou Y, Xu Y,Wang H*, Ye D, Liu H. Fluorescent Coumarin–Artemisinin Conjugates as Mitochondria-Targeting Theranostic Probes for Enhanced Anticancer Activities.Chemistry. 2015 Nov 23;21(48):17415-21. (*Corresponding author)

Ba Q, Li J, Huang C, Qiu H, Li J, Chu R,Zhang W, Xie D, Wu Y,Wang H*. Cumulative benzo(a)pyrene exposure promotes humanhepatocellular carcinoma angiogenesis and metastasis via NF-κB pathway.Environ Health Perspect. 2015 Mar;123(3):246-54. (*Corresponding author)

Ba Q, Li J, Huang C, Li J, Chu R, Wu Y,Wang H*. Topological, functional, and dynamic properties of the protein interaction networks rewired by benzo(a)pyrene.Toxicol Appl Pharmacol. 2015 Mar 1;283(2):83-91. (*Corresponding author)

Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, Liu C, Shen B, Wang XA, Wu W, Zhou D, Zhang D, Wang T, Liu B, Qu K, Ding Q, Weng H, Ding Q, Mu J, Shu Y, Bao R, Cao Y, Chen P, Liu T, Jiang L, Hu Y, Dong P, Gu J, Lu W, Shi W, Lu J, Gong W, Tang Z, Zhang Y, Wang X, Chin YE, Weng X, Zhang H, Tang W, Zheng Y, He L,Wang H*, Liu Y, Liu Y. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.Nat Genet. 2014 Aug;46(8):872-6. (*Corresponding author)

Li M, Chen P, Li J, Chu R, Xie D,Wang H*. The Impacts of Circulating 25-Hydroxyvitamin D Levels on Cancer Patient Outcomes: a Systematic Review and Meta-Analysis.J Clin Endocrinol Metab. 2014 Jul;99(7):2327-36. (*Corresponding author)

Chen P, Li C, Li X, Li J, Chu R,Wang H*. Higher dietary folate intake reduces the breast cancer risk: a systematic review and meta-analysis.Br J Cancer. 2014 Apr 29;110(9):2327-38. (*Corresponding author)

Li C, Chen P, Hu P, Li M, Li X, Guo H, Li J, Chu R, Zhang W,Wang H*. Folate intake and MTHFR polymorphism C677T is not associated with ovarian cancer risk: evidence from the meta-analysis.Mol Biol Rep. 2013 Dec;40(12):6547-60. (*Corresponding author)

Huang C, Ba Q, Yue Q, Li J, Li J, Chu R,Wang H*. Artemisinin rewires the protein interaction network in cancer cells: network analysis, pathway identification, and target prediction.Mol Biosyst. 2013 Dec 29;9(12):3091-100. (*Corresponding author)

Li J, Ba Q, Yin J, Wu S, Zhuan F, Xu S, Li J, Salazar JK, Zhang W,Wang H*. Surface Display of Recombinant Drosophila melanogaster Acetylcholinesterase for Detection of Organic Phosphorus and Carbamate Pesticides.PLoS ONE. 2013 Sep 9;8(9):e72986. (*Corresponding author)

Liu Y, Li C, Chen P, Li X, Li M, Guo H, Li J, Chu R,Wang H*. Polymorphisms in the vitamin D receptor (VDR) and the risk of ovarian cancer: a meta-analysis.PLoS ONE. 2013 Jun 24;8(6):e66716. (*Corresponding author)

Li M, Chen PZ, Yue QX, Li JQ, Chu RA, Zhang W,Wang H*. Pungent ginger components modulates human cytochrome P450 enzymes in vitro.Acta Pharmacol Sin. 2013 Sep 5;34(9):1237-42. (*Corresponding author)

Hou W, Qin X, Zhu X, Fei M, Liu P, Liu L, Moon H, Zhang P, Greshock J, Bachman KE, Ye BC,Wang H*, Zang CY. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.Oncol Rep. 2013 Aug;30(2):707-14. (*Corresponding author)

Ba Q, Duan J, Tian JQ, Wang ZL, Chen T, Li XG, Chen PZ, Wu SJ, Xiang L, Li JQ, Chu RA,Wang H*. Dihydroartemisinin promotes angiogenesis during the early embryonic development of zebrafish.Acta Pharmacol Sin. 2013 Aug;34(8):1101-7. (*Corresponding author)

Li X, Yang X, Liu Y, Gong N, Yao W, Chen P, Qin J, Jin H, Li J, Chu R, Shan L, Zhang R, Zhang W,Wang H*. Japonicone A suppresses growth of Burkitt’s lymphoma cells through its effect on NF-κB.Clin Cancer Res. 2013 Jun 1;19(11):2917-28. (*Corresponding author)

Li X ,Chen T, Lin S, Zhao J, Chen P, Ba Q, Guo H, Liu Y, Li J, Chu R, Shan L , Zhang W andWang H*. Valeriana jatamansi Constituent IVHD-valtrate As a Novel Therapeutic Agent to Human Ovarian Cancer: in vitro and in vivo Activities and Mechanisms.Curr Cancer Drug Targets. 2013 May 1;13(4):472-83. (*Corresponding author)

Zhang X, Wang W,Wang H, Wang MH, Xu W, Zhang R. Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop.Oncogene. 2013 May 30;32(22):2782-91.

Chen P, Li M, Gu X, Liu Y, Li X, Li C, Wang Y, Xie D, Wang F, Yu C, Li J, Chen X, Chu R, Zhu J, Ou Z,Wang H*. Higher Blood 25(OH)D Level May Reduce the Breast Cancer Risk: Evidence from a Chinese Population Based Case-Control Study and Meta-Analysis of the Observational Studies.PLoS ONE. 2013;8(1):e49312. (*Corresponding author)

Lin S, Zhang ZX, Chen T, Ye J, Dai WX, Shan L, Su J, Shen YH, Li HL, Liu RH, Xu XK,Wang H*, Zhang WD. Characterization of chlorinated valepotriates from Valeriana jatamansi.Phytochemistry. 2013 Jan;85:185-93. (*Corresponding author)

Ba Q, Zhou N, Duan J, Chen T, Hao M, Yang X, Li J, Yin J, Chu R,Wang H*. Dihydroartemisinin Exerts Its Anticancer Activity through Depleting Cellular Iron via Transferrin Receptor-1.PLoS ONE. 2012;7(8):e42703. (*Corresponding author)

Zhang X, Zhang Z, Cheng J, Li M, Wang W, Xu W,Wang H, Zhang R. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53.J Biol Chem. 2012 Aug 31;287(36):30468-76.

Ba Q, Hao M, Huang H, Hou J, Ge S, Zhang Z, Yin J, Chu R, Jiang H, Wang F, Chen K, Liu H andWang H*. Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies.Clin Cancer Res. 2011 Dec 15;17(24):7625-33. (*Corresponding author)

Chen T, Xu Y, Guo H, Liu Y, Hu P, Yang X, Li X, Ge S, Velu S, Nadkarni D, Wang W, Zhang R andWang H*. Experimental therapy of ovarian cancer with synthetic Makaluvamine Analog: In vitro and in vivo anticancer activity and molecular mechanisms of action.PLoS ONE. 2011;6(6):e20729. (*Corresponding author)

Duan J, Ba Q, Wang Z, Hao M, Hu P, Li X, Zhang D, Zhang R andWang H*. Knockdown of Ribosomal Protein S7 Causes Developmental Abnormalities via p53 Dependent and Independent Pathways in Zebrafish.Int J Biochem Cell Biol. 2011 Aug;43(8):1218-27. (*Corresponding author)

Guo D, Chen T, Ye D, Xu j, Jiang H, Chen K,Wang H*and Liu H. Cell-permeable Iminocoumarine-based Fluorescent Dyes for Mitochondria.Org Lett. 2011 Jun 3;13(11):2884-7. (*Corresponding author)

Li M, Zhou Y, Chen P, Yang H, Yuan X, Tajima K, Cao J andWang H*. Genetic Variants on Chromosome 8q24 and Colorectal Neoplasia Risk: A Case-control Study in China and a Meta-analysis of the Published Literature.PLoS ONE. 2011 Mar; 6(3):e18251. (*Corresponding author)

Hao M, Wang W, Zhao Y, Zhang R andWang H*. Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors.Eur J Drug Metab Pharmacokinet. 2011 Jan;35(3-4):109-13. (*Corresponding author)

Feng Y, Wang T, Deng Y, Yang P, Li J, Guan D, Yao F, Zhu Y, Qin Y, Wang H, Li N, Wu M,Wang H, Wang X, Cheng S and Xie D. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.Hepatology. 2011 Feb;53(2):483-92.

Hao M, Ba Q, Yin J, Li J, Zhao Y andWang H*. Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2 and CYP3A4 expression in HepG2 cells than glycosylated ginsenosides.Drug Metabolism and Pharmacokinetics. 2011;26(2):201-5. (*Corresponding author)

Tang H, Pang S, Wang M, Xiao X, Rong Y,Wang H, Zang YQ. TLR4 activation is required for IL-17-induced multiple tissue inflammation and wasting in mice.J Immunol. 2010 Aug 15;185(4):2563-9.

Liang J, Chen P, Hu Z, Shen H, Wang F, Chen L, Li M, Tang J,Wang H*and Shen H. Genetic variants in trinucleotide repeat-containing 9 (TNRC9) are associated with risk of estrogen receptor positive breast cancer in a Chinese population.Breast Cancer Res Treat. 2010 Nov;124(1):237-41. (*Corresponding author)

Feng Y, Ding X, Chen T, Chen L, Liu F, Jia X, Luo X, Shen X, Chen K, Jiang H,Wang H*, Liu H, Liu D. Design, synthesis and interaction study of quinazoline-2(1H)-thione derivatives as potential novel Bcl-xL Inhibitors.J Med Chem. 2010 May 13;53(9):3465-79. (*Corresponding author)

Lin S, Chen T, Liu XH, Shen YH, Li HL, Shan L, Liu RH, Xu XK, Zhang WD,Wang H*. Iridoids and Lignans from Valeriana jatamansi.J Nat Prod. 2010 Apr 23;73(4):632-8. (*Corresponding author)

Chen P, Hu P, Xie D, Qin Y, Wang F, andWang H*. Meta-analysis of Vitamin D, Calcium and the Prevention of Breast Cancer.Breast Cancer Res Treat. 2010 Jun;121(2):469-77. (*Corresponding author)

Chen T, Li M, Zhang R, andWang H*. Dihydroartemisinin Induces Apoptosis and Sensitizes Human Ovarian Cancer Cells to Carboplatin Therapy.J Cell Mol Med. 2009 Jul;13(7):1358-70. (*Corresponding author)

Lin S, Shen YH, Li HL, Yang XW, Chen T, Lu LH, Huang ZS, Liu RH, Xu XK, Zhang WD,Wang H*. Acylated iridoids with cytotoxicity from Valeriana jatamansi.J Nat Prod. 2009 Apr;72(4):650-5. (*Corresponding author)

Chen D, Zhang J, Li M, Rayburn ER,Wang H, Zhang R. RYBP stabilizes p53 by modulating MDM2.EMBO Rep. 2009 Feb;10(2):166-72.

Liang J, Chen P, Hu Z, Zhou X, Chen L, Li M, Wang Y, Tang J,Wang H*and Shen H. Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women.Carcinogenesis. 2008 Dec;29(12):2341-6. (*Corresponding author)

Chen P, Liang J, Wang Z, Zhou X, Chen L, Li M, Xie D, Hu Z, Shen H, andWang H*. Association of Common PALB2 Polymorphisms with Breast Cancer Risk: a Case-Control Study.Clin Cancer Res. 2008. Sep 15; 14 (8): 5931-37. (* Corresponding author)

Hou J, Wang D, Zhang R, andWang H*. Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action.Clin Cancer Res. 2008 Sep 1; 14(17):5519-30. (* Corresponding author)

Hao M, Zhao Y, Chen P, Huang H, Liu H, Zhang R, andWang H*. Structure-Activity Relationship and Substrate-dependent Phenomena in Effects of Ginsenosides on Activities of Drug-metabolizing P450 Isozymes.PLoS ONE. 2008 Jul 16;3(7):e2697. (* Corresponding author)

Wang W,Wang H*, Rayburn ER, Zhao Y, Hill DL, Zhang R. 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer: activity in vitro and in vivo and mechanisms of action.Br J Cancer. 2008 Feb 26;98(4):792-802. (*Co-first and Corresponding author)

Wang W, Rayburn ER, HaoM, Zhao Y, Hill DL, Zhang R,Wang H*. Experimental Therapy of Prostate Cancer with Novel Natural Product Anti-cancer Ginsenosides.Prostate. 2008 Mar 6;68(8):809-819 .(*Corresponding author)

1.

Wang H*

2.

Wang H*

3.

Wang H*

4.

Wang H*

5.

Wang H*

6.

Wang H*

7.

Wang H*

8.

Wang H*

9.

Wang H*

10.

Wang H*

11.

Wang H*

12.

Wang H*

13.

Wang H*

14.

Wang H*

15.

Wang H*

16.

Wang H*

17.

Wang H*

18.

Wang H

19.

Wang H*

20.

Wang H*

21.

Wang H*

22.

Wang H

23.

Wang H*

24.

Wang H*

25.

Wang H*

26.

Wang H*

27.

Wang H*

28.

Wang H*

29.

Wang H

30.

Wang H*

31.

Wang H

32.

Wang H*

33.

Wang H*

34.

Wang H*

35.

Wang H*

36.

Wang H*

37.

Wang H*

38.

Wang H

39.

Wang H*

40.

Wang H*

41.

Wang H*

42.

Wang H*

43.

Wang H*

44.

Wang H*